513 related articles for article (PubMed ID: 29196189)
1. PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.
Nallasamy P; Chava S; Verma SS; Mishra S; Gorantla S; Coulter DW; Byrareddy SN; Batra SK; Gupta SC; Challagundla KB
Semin Cancer Biol; 2018 Oct; 52(Pt 2):53-65. PubMed ID: 29196189
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs.
Ashrafizadeh M; Zarrabi A; Hushmandi K; Zarrin V; Moghadam ER; Zabolian A; Tavakol S; Samarghandian S; Najafi M
Life Sci; 2020 Sep; 256():117899. PubMed ID: 32504749
[TBL] [Abstract][Full Text] [Related]
4. Interplay between programmed death-ligand 1 and non-coding RNAs.
Ghafouri-Fard S; Shoorei H; Hussen BM; Poornajaf Y; Taheri M; Sharifi G
Front Immunol; 2022; 13():982902. PubMed ID: 36405753
[TBL] [Abstract][Full Text] [Related]
5. Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs.
Ding L; Lu S; Li Y
Pathol Oncol Res; 2020 Apr; 26(2):651-663. PubMed ID: 31748880
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma.
Tang XX; Shimada H; Ikegaki N
Genes Immun; 2022 Jun; 23(3-4):129-140. PubMed ID: 35525858
[TBL] [Abstract][Full Text] [Related]
8. Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.
Smolle MA; Calin HN; Pichler M; Calin GA
FEBS J; 2017 Jul; 284(13):1952-1966. PubMed ID: 28132417
[TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
[TBL] [Abstract][Full Text] [Related]
10. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Esophageal and Gastric Cancer.
Kelly RJ
Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
[TBL] [Abstract][Full Text] [Related]
12. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
[TBL] [Abstract][Full Text] [Related]
13. Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors.
Şener S; Poyraz A; Okur A; Pınarlı FG; Karadeniz C
Turk J Pediatr; 2021; 63(5):758-766. PubMed ID: 34738358
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
Barclay J; Creswell J; León J
Arch Esp Urol; 2018 May; 71(4):393-399. PubMed ID: 29745928
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].
Liao R; Sun XF; Zhen ZZ; Huang DS
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):735-740. PubMed ID: 30293276
[No Abstract] [Full Text] [Related]
17. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.
Wang X; Yang L; Huang F; Zhang Q; Liu S; Ma L; You Z
Immunol Lett; 2017 Apr; 184():7-14. PubMed ID: 28223102
[TBL] [Abstract][Full Text] [Related]
18. TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells.
Boes M; Meyer-Wentrup F
Cancer Lett; 2015 May; 361(1):49-56. PubMed ID: 25697485
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
20. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]